Sanofi's $1.1B eczema drug hits midphase goal, spurring talk of phase 3 and new indications

One of Sanofi’s priority assets has hit the primary endpoint in a phase 2b clinical trial. The candidate, which Sanofi snagged in its $1.1 billion Kymab buyout, improved outcomes in eczema patients, clearing the French drugmaker to push into phase 3 and boosting its prospects of targeting other diseases.